The Cheap Investor Exclusive

Cigna Keeps Winning. The Stock Keeps Losing.

Here’s a question worth sitting with for a moment.

If a company beat earnings estimates four quarters in a row, grew adjusted EPS by 16% year over year, raised its full-year outlook, and did all of that while the broader market ran to record highs, what would you expect the stock to do?

Most people would say: go up.

The Cigna Group (NYSE: CI) did none of that. The stock sits around $300 today, just modestly above its 52-week low of $239.51, and well below its 52-week high of $315.47. Trailing P/E is roughly 12x. Forward earnings multiple is somewhere in the 8 to 9 range. For a company guiding to at least $30.35 in adjusted EPS for 2026, that math is hard to ignore.

So what is the market seeing that the numbers are not telling us? And more importantly, is it right?

The Results Are Not the Problem

Start with what actually happened in Q1 2026, because the numbers deserve a proper look before we get into the fear.

Cigna reported total revenues of $68.5 billion, ahead of the $66.2 billion Wall Street had penciled in. Adjusted EPS came in at $7.79, beating the $7.60 estimate and representing 16% growth versus the same quarter a year ago. Management responded by lifting full-year 2026 adjusted EPS guidance to at least $30.35. Operating cash flow for the quarter was $1.1 billion.

That is four consecutive quarters of beating both EPS and revenue estimates. The company’s healthcare segment reported a medical care ratio of 79.8%, better than expected, driven partly by lower flu volumes. Evernorth, the health services engine that now generates roughly 85% of total company revenues, posted $58.4 billion in quarterly revenue, up 9% year over year. The Specialty and Care Services piece inside Evernorth grew pretax adjusted earnings 20% to $1.1 billion, driven by biosimilar adoption and specialty drug volume.

None of that reads like a company in distress.

Where the Fear Actually Lives

The discount is real. The question is whether it is earned.

Cigna’s problems are mostly not Cigna’s alone. The managed care sector has been one of the most unloved corners of the market for the better part of two years. The reasons are legitimate: rising medical utilization costs, Medicare Advantage rate uncertainty, political pressure on pharmacy benefit managers, and a broad investor exodus from anything with government reimbursement exposure. Bank of America, writing at the start of 2026, noted that “uncertainty best describes Managed Care” given overlapping questions around healthcare exchanges, Medicaid work requirements, and PBM reform.

For Cigna specifically, the most visible pressure point right now is Pharmacy Benefit Services. Pretax adjusted earnings in that segment fell 28% in Q1 to $394 million, driven by large client renewals and transition costs tied to Cigna’s new Signature model, a rebate-free PBM structure designed to pass drug savings directly to consumers. Pharmacy customers declined to 121 million at March 31, 2026, down from 123.6 million at year-end 2025. Total customer relationships fell to 185.5 million from 188.4 million.

Those are the numbers skeptics are watching. And they are real.

Slight tangent here, but it matters. The Signature model is an industry-scale bet on transparency at a moment when regulators are pushing the same direction. Evernorth has said the new reimbursement structure will roll out across all in-network pharmacies through 2026, with Cigna Healthcare adopting it for fully insured lives in 2027 and all Evernorth pharmacy clients by 2028. If that transition creates short-term earnings noise but positions the company ahead of where regulation is going anyway, that is a very different story than a business model that is structurally impaired.

What Cigna Actually Is in 2026

Most people still think of Cigna as a health insurer. That mental model is increasingly out of date.

Evernorth, built around the 2018 acquisition of Express Scripts, now drives the overwhelming majority of total revenues. It handles pharmacy benefit management, specialty pharmacy through Accredo, and a growing care services business. Pharmacy Benefit Services revenue actually grew 11% in Q1 to $33 billion, even as profitability compressed. And the part of Evernorth that is genuinely accelerating, Specialty and Care Services, posted 20% earnings growth in the quarter fueled by biosimilar adoption.

The biosimilar angle is worth understanding. Cigna has been offering biosimilars for Humira at $0 out of pocket for eligible patients, and the Stelara biosimilar program is in early-stage rollout now. Management has noted that approximately $100 billion in specialty drug spend in the U.S. is expected to become eligible for biosimilar substitution over the next five years. Evernorth’s scale in specialty pharmacy is directly positioned to capture that volume. Biosimilar switching is generally more profitable for Accredo than brand-name dispensing.

On top of that, Cigna launched an AI-powered specialty pharmacy program in July 2026 to reduce prescription processing times and improve patient support. Call volumes for digitally eligible members dropped 20% for Cigna Healthcare customers and 25% for Evernorth pharmacy customers versus two years ago. These are operational improvements that show up slowly in earnings, but they compound.

The Numbers at a Glance

• Q1 2026 revenue: $68.5 billion vs. estimate of $66.2 billion
• Q1 2026 adjusted EPS: $7.79 vs. estimate of $7.60, up 16% year over year
• Full-year 2026 adjusted EPS guidance: at least $30.35
• Evernorth revenues: $58.4 billion, up 9% year over year
• Specialty and Care Services pretax earnings: $1.1 billion, up 20%
• Pharmacy Benefit Services pretax earnings: $394 million, down 28%
• Cigna Healthcare medical care ratio: 79.8%
• Q1 operating cash flow: $1.1 billion
• Debt-to-capitalization ratio: 42.3% as of March 31
• Consecutive quarters beating EPS and revenue estimates: 4
• 52-week range: $239.51 to $315.47
• Current price (mid-July 2026): approximately $300
• Trailing P/E: approximately 12x
• Forward P/E: approximately 8 to 9x
• Average analyst price target: approximately $339 to $345 (median of 14 analyst targets near $339)
• Bernstein target: $381 (Outperform); UBS target: $400 (Buy); Barclays: $304 (Equal Weight)

Cheap, Fairly Valued, or a Trap?

This is the exercise that actually matters. A depressed valuation is not a thesis. It is a starting point.

The bear case has real substance. Pharmacy Benefit Services earnings are under pressure and the transition to the Signature model creates a multi-year period of compressed near-term profitability with uncertain client retention on the other side. Barclays downgraded CI in late May, flagging limited upside to earnings estimates and uncertainty around the PBM transition timeline. The firm also called out the upcoming September investor day as a key risk event. Customer counts are declining at the margin. And Brian Evanko, who became CEO on July 1 after David Cordani transitioned to Executive Chair, inherits a genuinely complex strategic moment.

The bull case is more straightforward, which is sometimes a good sign. The Evernorth specialty and biosimilar businesses are growing fast and sit in a structurally favorable position as expensive brand-name drugs lose patent protection over the next five years. The Signature model may compress earnings now, but it aligns with the regulatory direction of travel, which could prove to be a competitive advantage by 2027 and 2028 as slower-moving rivals scramble to adapt. The valuation, at 8 to 9 times forward earnings, already reflects a lot of bad news. UBS has a $400 target on the stock. Bernstein sees $381. The median of 14 analyst targets sits near $339, roughly 13% above where the stock trades today.

What’s interesting is the institutional picture. Davis Selected Advisers added nearly 1.5 million shares in Q1 2026, up almost 200%. GMO added 640,000 shares, up 33%. AQR added nearly 1 million shares. These are not momentum buyers. These are value-oriented institutions who have looked at the same data and concluded the discount is excessive.

Our read: this looks more like temporary compression than structural impairment. But the Q2 results on July 30 are the next real test, and the Pharmacy Benefit Services line is the one to watch closely.

Three Scenarios

• Bull case: Specialty and Care Services continues its 20%-plus earnings growth trajectory. Biosimilar volume keeps expanding as Stelara adoption ramps and new drugs come off patent. The Signature model proves sticky with clients and begins contributing to earnings stabilization by late 2026. The sector overhang lifts further as Medicaid and Medicare Advantage policy clarity improves. CI closes the gap toward the analyst consensus target around $340, representing roughly 13% upside from current levels, with further potential beyond that if the multiple begins to normalize.
• Base case: Cigna delivers on its raised 2026 guidance of at least $30.35 adjusted EPS. Pharmacy Benefit Services earnings stabilize in the second half, Evernorth Specialty continues to grow, and sentiment toward managed care slowly improves. Stock grinds toward the high $310 to $330 range by year-end. Modest multiple expansion from a very compressed starting point.
• Bear case: Large client relationships in Pharmacy Benefit Services deteriorate further. The Signature model struggles with adoption, creating more earnings pressure without the expected payoff. Regulatory action on PBMs intensifies beyond current expectations. Customer count declines accelerate. The earnings base proves less durable than management’s guidance implies, and the stock revisits its 2026 lows.

Cheap Investor Scorecard

What Patient Investors Should Watch

July 30 is the next data point. Q2 2026 results.

The headline EPS number will matter less than two specific line items. First, Pharmacy Benefit Services pretax earnings. A second consecutive quarter of sharp decline would raise legitimate questions about whether the Signature transition is more damaging than management has indicated. Stabilization, even modest stabilization, would be a meaningful signal. Second, customer counts. If pharmacy customers continue declining from the 121 million reported at quarter-end March, that is worth taking seriously.

If those two items hold or improve, the investment case becomes considerably cleaner. At 8 to 9 times forward earnings, a company delivering $30-plus in annual EPS with a growing specialty pharmacy business and a biosimilar runway stretching years into the future looks like the kind of disconnect this publication exists to find.

If they deteriorate further, the market’s skepticism may be better calibrated than it appears.

The September investor day is also worth circling. New CEO Brian Evanko will need to lay out a clear picture of where earnings go from here, how quickly the Signature model begins contributing positively, and what the long-term margin profile looks like as the PBM business transforms. That presentation will likely do more to move the stock than any single quarterly result.

For now, Cigna is one of the few large-cap healthcare businesses trading at a genuine discount to its own fundamental earning power. Whether the market’s skepticism is prescient or excessive is the question. The answer starts arriving on July 30.

This editorial is for informational and educational purposes only and does not constitute individual investment advice. All data sourced from company filings, earnings call transcripts, analyst reports, and publicly available financial data as of mid-July 2026. Verify all figures independently before making any investment decision.